Paper40078286
High-performance PBPK model for predicting CYP3A4 induction-mediated drug interactions: a refined and validated approach.
Yang CG and 5 others. Front Pharmacol, 2025. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. High-performance PBPK model for predicting CYP3A4 induction-mediated drug interactions: a refined and validated approach. Papers, record 40078286. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40078286
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- High-performance PBPK model for predicting CYP3A4 induction-mediated drug interactions: a refined and validated approach.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References52
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25851638 | Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist. | J Clin Pharmacol | 2015 | https://conductscience.org/library/papers/25851638 | PubMed |
| 2 | 26953185 | Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL-2 Inhibitor: Results of a Single- and Multiple-Dose Study. | J Clin Pharmacol | 2016 | https://conductscience.org/library/papers/26953185 | PubMed |
| 3 | 26385839 | Physiologically-Based Pharmacokinetic Modeling of Macitentan: Prediction of Drug-Drug Interactions. | Clin Pharmacokinet | 2016 | https://conductscience.org/library/papers/26385839 | PubMed |
| 4 | 27506419 | New brominated flame retardants and their metabolites as activators of the pregnane X receptor. | Toxicol Lett | 2016 | https://conductscience.org/library/papers/27506419 | PubMed |
| 5 | 32387584 | Early discontinuation of tofacitinib in patients with rheumatoid arthritis co-treated with rifampin for latent tuberculosis. | Joint Bone Spine | 2020 | https://conductscience.org/library/papers/32387584 | PubMed |
| 6 | 27128004 | Impact on abiraterone pharmacokinetics and safety: Open-label drug-drug interaction studies with ketoconazole and rifampicin. | Clin Pharmacol Drug Dev | 2015 | https://conductscience.org/library/papers/27128004 | PubMed |
| 7 | 4087830 | Pharmacokinetics of oral and intravenous rifampicin during chronic administration. | Klin Wochenschr | 1985 | https://conductscience.org/library/papers/4087830 | PubMed |
| 8 | 26749408 | Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa. | Am J Cardiovasc Drugs | 2016 | https://conductscience.org/library/papers/26749408 | PubMed |
| 9 | 23852652 | Effects of cytochrome P450 inhibitors and inducers on the metabolism and pharmacokinetics of ospemifene. | Biopharm Drug Dispos | 2013 | https://conductscience.org/library/papers/23852652 | PubMed |
| 10 | 24530864 | Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: influence of time between substrate and inducer administration. | Eur J Pharm Sci | 2014 | https://conductscience.org/library/papers/24530864 | PubMed |
| 11 | 21036951 | Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions. | Drug Metab Dispos | 2011 | https://conductscience.org/library/papers/21036951 | PubMed |
| 12 | 28912253 | Physiologically Based Pharmacokinetic Model Predictions of Panobinostat (LBH589) as a Victim and Perpetrator of Drug-Drug Interactions. | Drug Metab Dispos | 2017 | https://conductscience.org/library/papers/28912253 | PubMed |
| 13 | 21602517 | The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. | J Clin Pharmacol | 2012 | https://conductscience.org/library/papers/21602517 | PubMed |
| 14 | 23995268 | Evaluation of various static and dynamic modeling methods to predict clinical CYP3A induction using in vitro CYP3A4 mRNA induction data. | Clin Pharmacol Ther | 2014 | https://conductscience.org/library/papers/23995268 | PubMed |
| 15 | 31145690 | Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions. | Drug Metab Pers Ther | 2019 | https://conductscience.org/library/papers/31145690 | PubMed |
| 16 | 34902744 | Development and application of a physiologically based pharmacokinetic model for entrectinib in rats and scale-up to humans: Route-dependent gut wall metabolism. | Biomed Pharmacother | 2022 | https://conductscience.org/library/papers/34902744 | PubMed |
| 17 | 27367453 | Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling. | Clin Pharmacol Ther | 2016 | https://conductscience.org/library/papers/27367453 | PubMed |
| 18 | 24086247 | Modeling of rifampicin-induced CYP3A4 activation dynamics for the prediction of clinical drug-drug interactions from in vitro data. | PLoS One | 2013 | https://conductscience.org/library/papers/24086247 | PubMed |
| 19 | 24962564 | The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers. | Br J Clin Pharmacol | 2014 | https://conductscience.org/library/papers/24962564 | PubMed |
| 20 | 19843061 | Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects. | Br J Clin Pharmacol | 2009 | https://conductscience.org/library/papers/19843061 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42865646 | Microbiota-based PBPK model: new approach methodology for assessing the kinetics of drugs and chemicals. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42865646 | PubMed |
| 41788629 | Predicting drug-drug interactions between ayahuasca alkaloids and SSRIs using physiologically based pharmacokinetic modeling. | Front Mol Biosci | 2026 | https://conductscience.org/library/papers/41788629 | PubMed |
| 40642005 | Editorial: Application of PKPD modeling in drug discovery and development. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40642005 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CYP3A4 | 1576 | PubTator's text mining | https://conductscience.org/library/genes/1576 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40078286
GET https://conductscience.org/api/papers/v1/40078286/references?page=2